AMGEN and MERCK announced an agreement to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a phase Ib/II study in mid- to late-stage melanoma.
HEALTH CANADA approved the Aptima HPV 16 18/45 genotype assay for use on the Panther system, both developed by Hologic Inc. The assay is the only approved test for genotyping human papillomavirus types 16, 18 and/or 45 in Canada.
DEFINIENS and Clarient Diagnostic Services Inc. signed an agreement to extend the use of Definiens' automated image analysis software and solutions in Clarient's validated clinical applications for immunohistochemistry testing in breast cancer.
THE UNIVERSITY OF PITTSBURGH selected GenomOncology's GenomAnalytics platform and services to explore and mine the data in The Cancer Genome Atlas.
SARAH CANNON CANCER CENTER and HealthONE hospitals launched an initiative to fully integrate their cancer programs by the end of 2014.
RICHARD FOLKERS was named director of communications for the Foundation for the NIH.
DANA-FARBER CANCER INSTITUTE was awarded a $900,000 grant from the Ovarian Cancer Research Fund to test new combinations of targeted drugs against the disease.
THE NATIONAL COALITION FOR CANCER RESEARCH elected members to its board of directors. Wendy Selig was elected president.
THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO and Quest Diagnostics formed a collaboration to research advanced diagnostics in the field of precision medicine. Initial clinical areas of focus include autism, oncology, neurology and women's health.
ANGELA DAVIES was appointed chief medical officer of Champions Oncology.
